Incidence and baseline predictors of discontinuation in DRCRnet studies - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Prevalence and Initial Predictors of Treatment Discontinuation in DRCRnet Research Studies

  • By

  • Klyve N. Otinkorang

  • Gui-shuang Ying

  • September 11, 2026

Share

Objective:

To assess discontinuation rates and identify baseline predictors of treatment discontinuation in diabetic retinopathy (DR) studies using DRCRnet datasets.

Approach:
  • Study Design: Secondary analysis of publicly available, de-identified data from 19 DRCRnet studies conducted from 2003 to 2020.
  • Outcome Measure: Discontinuation defined as participant departure from a study before completion, excluding deaths.
  • Statistical Analysis: Univariable and multivariable logistic regression analyses were performed to identify predictors of discontinuation.
Key Findings:
  • Out of 7770 participants, 7353 were included after exclusions, resulting in a discontinuation rate of X%.
  • Demographic and clinical characteristics were analyzed to identify predictors of discontinuation, including age, sex, race/ethnicity, and baseline health conditions.
Limitations:
  • The analysis is based on secondary data, which may have inconsistencies.
  • Certain health conditions (e.g., dyslipidaemia) had incomplete data.
Conclusion:

Identifying predictors of treatment discontinuation can provide insights into participant retention in diabetic retinopathy research.

Sources:

Original Source(s)

Incidence and baseline predictors of discontinuation in DRCRnet studies

  • by Klyve N. Otinkorang, Gui-shuang Ying

  • September 11, 2026

Related Content

Diagnosis Gaps Mark Retinopathy Care

A US systematic review found substantial losses across diabetic retinopathy screening, diagnosis awareness, referral, and follow-up.

Can Patients Switch to Biosimilar Aflibercept?

A 20-week INSIGHT extension suggests that switching from reference aflibercept to MYL-1701P maintained comparable safety, visual, and anatomic outcomes in patients with diabetic macular edema.

Phenotype-driven management of diabetic macular edema: multimodal imaging biomarkers and individualized therapy